Naproxen/Omeprazole

萘普生/奥美拉唑

Report date: 2022/11/25 17:42:31

Base Information

Drug NameNaproxen/Omeprazole
Drug Alias Name奥美拉唑/萘普生Omeprazole/NaproxenPN-200
ClassificationSmall molecules
Mechanisms of ActionCyclooxygenases inhibitorsProton pump inhibitors
TargetsProton pumpCyclooxygenases
Therapy Area/IndicationsOsteoarthritisArthritis, RheumatoidSpondylitis, Ankylosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes NaproxenOmeprazole
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAralez Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAutobahn Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsOsteoarthritisArthritis, RheumatoidSpondylitis, Ankylosing

Other Information

ATC CodeN/A
Related LinksN/A